Figure1.

Genomic Alterations Found in Each patient’s Tumor are Shown. No Co-Occurring Mutations in EGFR, ALK, or KRAS Were Seen, Although Mutations in TP53 Co-Occurred With BRAF Mutations in 28% of Patients. Most Patients had Only a Few Secondary Genomic Alterations Detected, With the Exception of 1 Patient (Case #11) Whose Tumor had Mutations And/or Exon Deletions in Multiple Genes as Identified by Next-Generation Sequencing. In the figure, BRAF Mutations are Highlighted in Red, and Other Mutations are Highlighted in Blue